Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
simvastatin + omega-3-acid ethyl esters
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Simvastatin + omega-3-acid ethyl esters is a fixed-dose combination therapy used primarily for the management of mixed dyslipidemia, particularly in patients with elevated triglycerides and cholesterol levels. Simvastatin is a synthetic prodrug that acts as an HMG-CoA reductase inhibitor (statin), reducing cholesterol synthesis in the liver and lowering LDL-cholesterol. Omega-3-acid ethyl esters are composed mainly of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in their ethyl ester forms, which lower triglyceride levels by reducing hepatic production of very low-density lipoprotein (VLDL). The combination has been shown to provide additive or synergistic effects on lipid parameters, including reductions in non-HDL cholesterol, VLDL cholesterol, total cholesterol, triglycerides, and improvements in HDL cholesterol. This therapeutic approach is especially useful for patients whose lipid profiles are not adequately controlled by statins alone[4][5]. Simvastatin was originally developed by Merck; Lovaza (omega-3-acid ethyl esters) was developed by Reliant Pharmaceuticals/GlaxoSmithKline.
- Brand names
- Lovaza + Zocor
- Other names
- EPA/DHA combinationprescription omega-3 acid ethyl estersP-OM3P-OM-3P-OM 3
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on simvastatin + omega-3-acid ethyl esters.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on simvastatin + omega-3-acid ethyl esters.